Антидепрессивная активность клавулановой кислоты не подтвердилась

The randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 mg and 5 mg, to placebo over an 8-week treatment period. Results from the study did not demonstrate Serdaxin's efficacy compared to placebo measured by the Montgomery-Asberg Depression Rating Scale (MADRS).

Rexahn Pharmaceuticals Announces Phase II Results for Serdaxin as Treatment for Major Depressive Disorder

Сердаксин

A new drug slated to undergo clinical study for major depressive disorder (MDD) shows promise for delivering the needed therapeutic effect to patients without triggering some of the more common side effects associated with anti-depressants.

Specifically, the drug provides a unique method of action that works as a dual enhancer of serotonin and dopamine in the brain.

Phase IIb Study of Serdaxin Underway for Treatment of Major Depressive Disorder